UPC sees rising small molecule litigation with Pfizer in the hot seat

A rare “innovator v innovator” case puts Pfizer in the firing line over its COVID-19 drug, highlighting the Unified Patent Court as an attractive forum for ‘David vs Goliath’ scenarios, say experts.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

UPC orders Sanofi to fix ‘deficiencies’ in prostate cancer drug case

28 January 2025 Munich division asks pharma company for clarity on territorial scope | Sanofi took battle with four generic makers over Jevtana to UPC.

Europe

Life sciences cases at the UPC will surely rise, but is the court prepared?

18 June 2024 Signs show that an uptick of life sciences cases at the Unified Patent Court is likely, but does the court have capacity? Anna Leathley, Richard Newell & Sarah Mitchell of Carpmaels & Ransford explore.

Big Pharma

Pfizer sued over COVID-19 antiviral drug

28 June 2022 Pfizer is facing a lawsuit centring on its COVID-19 antiviral, Paxlovid, after Enanta Pharmaceuticals filed a complaint citing patent infringement.

More features

Scientist jumps from Jones Day to expand rival’s biotech offering

AIPPI: Personalised medicine tests the limits in patent law

Ropes & Gray loses 21-attorney group to join rival on growth spree

How 'Boehringer' sets preliminary relief threshold for generics

‘Whose trademark law is AI based on exactly?’: Key questions from Marques

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

UPC sees rising small molecule litigation with Pfizer in the hot seat

More on this story

Editor's picks

Editor's picks

More features